Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
100% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. VNDA: No Debt )
VNDA' s 10-Year Cash to Debt Range
Min: 44.31   Max: No Debt
Current: No Debt

Equity to Asset 0.94
VNDA's Equity to Asset is ranked higher than
96% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VNDA: 0.94 )
VNDA' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.94
Current: 0.94

0.07
0.94
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
64% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
VNDA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 22.33
M-Score: 2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 40.00
VNDA's Operating margin (%) is ranked higher than
98% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. VNDA: 40.00 )
VNDA' s 10-Year Operating margin (%) Range
Min: -28023.53   Max: 40
Current: 40

-28023.53
40
Net-margin (%) 40.24
VNDA's Net-margin (%) is ranked higher than
97% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. VNDA: 40.24 )
VNDA' s 10-Year Net-margin (%) Range
Min: -27864.71   Max: 40.25
Current: 40.24

-27864.71
40.25
ROE (%) 44.29
VNDA's ROE (%) is ranked higher than
98% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. VNDA: 44.29 )
VNDA' s 10-Year ROE (%) Range
Min: -221.21   Max: 23.67
Current: 44.29

-221.21
23.67
ROA (%) 16.78
VNDA's ROA (%) is ranked higher than
96% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. VNDA: 16.78 )
VNDA' s 10-Year ROA (%) Range
Min: -176.39   Max: 12.81
Current: 16.78

-176.39
12.81
ROC (Joel Greenblatt) (%) 646.71
VNDA's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. VNDA: 646.71 )
VNDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4993.01   Max: 784.55
Current: 646.71

-4993.01
784.55
Revenue Growth (3Y)(%) 7.30
VNDA's Revenue Growth (3Y)(%) is ranked higher than
79% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. VNDA: 7.30 )
VNDA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 89.7
Current: 7.3

0
89.7
» VNDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VNDA Guru Trades in Q1 2014

John Paulson 1,392,500 sh (New)
» More
Q2 2014

VNDA Guru Trades in Q2 2014

John Paulson 3,200,000 sh (+129.80%)
» More
Q3 2014

VNDA Guru Trades in Q3 2014

John Paulson 3,250,000 sh (+1.56%)
» More
Q4 2014

VNDA Guru Trades in Q4 2014

John Paulson 3,625,000 sh (+11.54%)
John Paulson 3,625,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Vanda Pharmaceuticals Inc

John Paulson's 4 Stocks Trading for Less Than He Paid for Them
John Paulson (Trades, Portfolio)’s firm Paulson & Co. manages approximately $21.4 billion and focuses specifically on arbitrage strategies, restructurings and other capital events. When his team analyzes stocks undergoing corporate events or sectors in which they have interest, they employ a bottom-up assessment of fundamentals within those targets. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 144.80
VNDA's P/E(ttm) is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 144.80 )
VNDA' s 10-Year P/E(ttm) Range
Min: 29.59   Max: 217.54
Current: 144.8

29.59
217.54
Forward P/E 31.06
VNDA's Forward P/E is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 31.06 )
N/A
PE(NRI) 143.60
VNDA's PE(NRI) is ranked higher than
89% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 143.60 )
VNDA' s 10-Year PE(NRI) Range
Min: 28   Max: 214.43
Current: 143.6

28
214.43
P/B 2.10
VNDA's P/B is ranked higher than
89% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. VNDA: 2.10 )
VNDA' s 10-Year P/B Range
Min: 1.95   Max: 540.33
Current: 2.1

1.95
540.33
P/S 7.29
VNDA's P/S is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. VNDA: 7.29 )
VNDA' s 10-Year P/S Range
Min: 2.62   Max: 69.06
Current: 7.29

2.62
69.06
EV-to-EBIT 14.39
VNDA's EV-to-EBIT is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 14.39 )
VNDA' s 10-Year EV-to-EBIT Range
Min: -1288.6   Max: 578.2
Current: 14.39

-1288.6
578.2
Current Ratio 18.20
VNDA's Current Ratio is ranked higher than
94% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. VNDA: 18.20 )
VNDA' s 10-Year Current Ratio Range
Min: 3.71   Max: 18.2
Current: 18.2

3.71
18.2
Quick Ratio 17.54
VNDA's Quick Ratio is ranked higher than
94% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. VNDA: 17.54 )
VNDA' s 10-Year Quick Ratio Range
Min: 3.71   Max: 17.54
Current: 17.54

3.71
17.54
Days Inventory 344.52
VNDA's Days Inventory is ranked higher than
78% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 344.52 )
VNDA' s 10-Year Days Inventory Range
Min: 80.64   Max: 596.04
Current: 344.52

80.64
596.04
Days Sales Outstanding 26.59
VNDA's Days Sales Outstanding is ranked higher than
93% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. VNDA: 26.59 )
VNDA' s 10-Year Days Sales Outstanding Range
Min: 5.22   Max: 253.93
Current: 26.59

5.22
253.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
VNDA's Price/Net Cash is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. VNDA: 2.80 )
VNDA' s 10-Year Price/Net Cash Range
Min: 0.31   Max: 125
Current: 2.8

0.31
125
Price/Net Current Asset Value 2.70
VNDA's Price/Net Current Asset Value is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. VNDA: 2.70 )
VNDA' s 10-Year Price/Net Current Asset Value Range
Min: 0.3   Max: 185
Current: 2.7

0.3
185
Price/Tangible Book 2.50
VNDA's Price/Tangible Book is ranked higher than
90% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. VNDA: 2.50 )
VNDA' s 10-Year Price/Tangible Book Range
Min: 0.29   Max: 392
Current: 2.5

0.29
392
Price/DCF (Projected) 5.90
VNDA's Price/DCF (Projected) is ranked higher than
92% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 5.90 )
VNDA' s 10-Year Price/DCF (Projected) Range
Min: 5.67   Max: 8.42
Current: 5.9

5.67
8.42
Price/Median PS Value 1.00
VNDA's Price/Median PS Value is ranked higher than
86% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. VNDA: 1.00 )
VNDA' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 9.3
Current: 1

0.45
9.3
Price/Graham Number 1.40
VNDA's Price/Graham Number is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VNDA: 1.40 )
VNDA' s 10-Year Price/Graham Number Range
Min: 1.97   Max: 3.93
Current: 1.4

1.97
3.93
Earnings Yield (Greenblatt) 6.90
VNDA's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. VNDA: 6.90 )
VNDA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 3521.3
Current: 6.9

0.2
3521.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals Inc was incorporated in Delaware in 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. It operates in one business segment which is the development and commercialization of pharmaceutical products. Its product portfolio includes: HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt, a product for the treatment of schizophrenia, the oral formulation of which is currently being marketed and sold in the U.S. by Novartis Pharma AG; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities.
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
comment on VNDA Nov 12 2012 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
$VNDA New study started: Oct 15 2010 
Hourly trend UP Aug 11 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
upgraded to BUY Jul 07 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
7:44 am Vanda Pharma confirms a positive CHMP Opinion for HETLIOZ, to treat non-24-hour sleep-wake... Apr 26 2015
Nasdaq stocks posting largest percentage decreases Apr 24 2015
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 24 2015
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour... Apr 24 2015
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour... Apr 24 2015
Vanda Pharmaceuticals Announces the Appointment of Chief Commercial Officer Apr 20 2015
Vanda Pharmaceuticals Announces the Appointment of Chief Commercial Officer Apr 20 2015
Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 Apr 16 2015
Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 Apr 16 2015
Vanda Announces Trial Date for Fanapt® Patent Cases Apr 13 2015
Vanda Announces Trial Date for Fanapt® Patent Cases Apr 13 2015
Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book Apr 09 2015
Vanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book Apr 09 2015
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 20 2015
VANDA PHARMACEUTICALS INC. Financials Mar 20 2015
VANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Mar 13 2015
Vanda Down after Candidate Disappoints in Phase II Study - Analyst Blog Mar 09 2015
Vanda's eczema drug fails mid-stage study, shares fall Mar 04 2015
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 04 2015
Vanda's eczema drug fails mid-stage study Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK